Pharmacological targets at the lysosomal autophagy-NLRP3 inflammasome crossroads.

导出原文传递

翻译打印收藏纠错

作者： Srinivasa Reddy,Bonam ^[1] ; Dylan,Mastrippolito ^[2] ; Philippe,Georgel ^[3] ; Sylviane,Muller ^[4]

作者单位： Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. ^[1] CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France; Strasbourg Institute of Drug Discovery and Development (IMS), Strasbourg, France. ^[2] CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France; Strasbourg Institute of Drug Discovery and Development (IMS), Strasbourg, France; Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg University, Strasbourg, France. ^[3] CNRS-University of Strasbourg, Biotechnology and Cell Signaling, Illkirch, France; Strasbourg Institute of Drug Discovery and Development (IMS), Strasbourg, France; Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg University, Strasbourg, France; University of Strasbourg Institute for Advanced Study (USIAS), Strasbourg, France. Electronic address: sylviane.muller@unistra.fr. ^[4]

关键词 NLRP3 inflammasome–autophagy regulation drugs low-grade systemic inflammation lysosomal dysfunction

主题词人类(Humans);炎性体(Inflammasomes);自噬(Autophagy);炎症(Inflammation);溶酶体(Lysosomes)

DOI 10.1016/j.tips.2023.11.005

PMID 38102020

发布时间 2024-03-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交